|Bid||0.00 x 1400|
|Ask||0.00 x 1300|
|Day's Range||222.18 - 223.00|
|52 Week Range||165.30 - 223.88|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.43%|
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date). In the same period, the S&P 500 has risen ~8%. Abbott Laboratories has clearly surpassed the market’s returns so far in 2018.
Today, Zimmer Biomet Holdings (ZBH) is trading at $128.82, which represents a ~2.08% rise from yesterday’s close of $126.19.
One of the primary benefits of the exchange-traded fund (ETF) space at this stage is that investors have an incredible degree of flexibility. Below, we'll examine some of the benefits and risks of thematic ETFs that any investor should consider before setting aside assets for investment. One of the major concerns when it comes to thematic ETFs is volatility.
Thermo Fisher Scientific (TMO) provides equipment, software, analytical instruments, reagents, consumables, and services. Thermo Fisher reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion, a 21.8% increase as compared to ~$5.0 billion during the second quarter of 2017. The below chart compares revenues and EPS for Thermo Fisher Scientific since the first quarter of 2017.
The iShares U.S. Medical Devices ETF (IHI) and the SPDR S&P Health Care Equipment ETF (XHE), both medical device funds, have returned 26.8% and $37%, respectively, in 2018 YTD (year-to-date). That’s significantly higher than the SPDR S&P 500 ETF (SPY) at 9.7% for the same period.
How Do Abiomed’s Valuations Look in September? Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018. The earnings per share are expected to be $4.66 in 2019.
Illumina (ILMN) reached its 52-week high of $357.93 per share on August 31. On August 28, Illumina’s MiSeqDx sequencing system received approval in China. On August 16, ILMN stock fell ~2.1% in after-hours trading due to the news of the company’s plans to offer $650 million of convertible senior notes, which will be due by 2023.
Today, Align Technology (ALGN) reported a 52-week high of $392.69 per share. The stock momentum has seen strong growth momentum this year on strong quarterly performances and fundamentals. Align is currently trading higher than its 50-day moving average of $366.00 and its 200-day moving average of $308.74. The stock was trading at a 52-week low of $173.88 per share on September 1, 2017.
Becton Dickinson (BDX) generated revenues of $4.3 billion in the fiscal third quarter compared to $1.5 billion in the fiscal third quarter of 2017, reflecting a ~41% YoY (year-over-year) growth. The acquisition of C.R. Bard primarily contributed to Becton Dickinson’s revenue growth in the third quarter.
While technology stocks tend to make the flashiest headlines, the health-care sector remains one of the most consistent outperformers. The top health-care exchange traded fund (ETF) by assets, the $18 billion Health Care Select SPDR ETF (XLV) has gained about 10% this year vs. 6% for the S&P 500 Index (SPX) And longer term, it’s up about 205% in 10 years vs. about 145% for the S&P 500. It’s no surprise, then, that investors closely follow these health-care funds and continue to invest plenty of funds in the leaders.
On a relative basis, the sector continues to digest its strong year-to-date gains and work off a bearish momentum divergence by consolidating above our previous price objective at 0.734. An individual name in the sector breaking out is Masimo Corporation ( MASI). It has been consolidating for the past 18 months, and this push to new all-time highs signals the resumption of its long-term uptrend.
Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.
Shares of automotive companies climbed last Thursday as U.S. President Donald Trump eased the car tariff threat following a meeting with European Commission President Jean-Claude Juncker.
On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.
Pharmaceutical company Thermo Fisher Scientific (TMO) is set to release its second-quarter earnings on July 25. Wall Street analysts expect the company to report EPS of $2.62 on revenues of $5.9 billion during the second quarter.
Medical device stocks and the related ETFs are among the brightest spots in the broader healthcare sector this year. iShares U.S. Medical Devices ETF (NYSEArca: IHI), the largest dedicated medical devices ...
Investors looking for a sector level summer rental in the financial markets may want to consider healthcare ETFs, such as the Health Care Select Sector SPDR (XLV). XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks. There are other catalysts to consider, including that the U.S. economy is moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up.
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.